Treating malignant melanoma when a rare BRAF V600M mutation is present: case report and literature review
Recent years have brought major advances in the treatment of malignant melanoma. One such an advance is the treatment with BRAF tyrosine-kinase inhibitors in metastatic malignant melanomas that harbor mutations in the BRAF gene. The trials that have been performed in this setting have demonstrated s...
Main Authors: | Popescu Andrei, Haidar Andrei, Anghel Rodica Maricela |
---|---|
Format: | Article |
Language: | English |
Published: |
Sciendo
2018-06-01
|
Series: | Romanian Journal of Internal Medicine |
Subjects: | |
Online Access: | https://doi.org/10.1515/rjim-2017-0044 |
Similar Items
-
Pharmacoeconomic analysis of vemurafenib and dabrafenib use in patients with inoperable or metastatic melanoma with BRAF V600 mutation
by: A. S. Kolbin, et al.
Published: (2018-05-01) -
Real-World Experience with Targeted Therapy in BRAF Mutant Advanced Melanoma Patients: Results from a Multicenter Retrospective Observational Study Advanced Melanoma in Russia (Experience) (ADMIRE)
by: Kristina V. Orlova, et al.
Published: (2021-05-01) -
Long-Term Outcomes of Targeted Therapy after First-Line Immunotherapy in BRAF-Mutated Advanced Cutaneous Melanoma Patients—Real-World Evidence
by: Paweł Rogala, et al.
Published: (2022-04-01) -
Diverse Mechanisms of BRAF Inhibitor Resistance in Melanoma Identified in Clinical and Preclinical Studies
by: Stephen A. Luebker, et al.
Published: (2019-04-01) -
Early Experience with Dabrafenib–Trametinib Combination in Patients with BRAF-Mutated Malignant Melanoma—A Single-Center Experience
by: Sandip Ganguly, et al.
Published: (2021-09-01)